Taysha Gene Therapies (TSHA) Treasury Shares (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Treasury Shares data on file, last reported at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 74.29% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 74.29% YoY), and the FY2025 full-year result was $6.3 million, up 38.73% from the prior year.
• Treasury Shares climbed to $10.9 million in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $10.9 million in Q1 2026 to a low of $85494.0 in Q4 2022.
• A 5-year average of $3.5 million and a median of $3.2 million in 2022 frame the typical range for Treasury Shares.
• Across the five-year window, Treasury Shares slumped 95.47% in 2022 and surged 1112.97% in 2024, its largest moves.
• Tracing TSHA's Treasury Shares over 5 years: stood at $85494.0 in 2022, then surged by 338.68% to $375044.0 in 2023, then surged by 1112.97% to $4.5 million in 2024, then surged by 38.73% to $6.3 million in 2025, then surged by 72.37% to $10.9 million in 2026.
• Business Quant data shows TSHA's Treasury Shares at $10.9 million in Q1 2026, $6.3 million in Q4 2025, and $6.3 million in Q3 2025.